{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T11:02:59Z","timestamp":1779793379622,"version":"3.53.1"},"reference-count":80,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.dmd.2026.100295","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T17:00:49Z","timestamp":1775754049000},"page":"100295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["In Vitro Reaction Phenotyping and Projection of Drug Interactions Mediated by Cytochrome P450 Enzymes for Central Nervous System Drugs as Victims: Implications for Safety in Vulnerable Populations"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7493-4920","authenticated-orcid":false,"given":"Veera Raghava Chowdary","family":"Palacharla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2045-0784","authenticated-orcid":false,"given":"Ramakrishna","family":"Nirogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Jayarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6859-1916","authenticated-orcid":false,"given":"Hanumanth Rao","family":"Pantangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4486-0786","authenticated-orcid":false,"given":"Surendra","family":"Petlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnadas","family":"Nandakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.dmd.2026.100295_bib1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","article-title":"Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"23","year":"2024","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.dmd.2026.100295_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70546","article-title":"Multimorbidity in dementia: current perspectives and future challenges","volume":"21","author":"Stirland","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.dmd.2026.100295_bib3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1590\/0004-282x-anp-2020-0091","article-title":"Multimorbidity and associated outcomes among older adult inpatients with neurological disorders","volume":"79","author":"Bacellar","year":"2021","journal-title":"Arq Neuropsiquiatr"},{"issue":"7","key":"10.1016\/j.dmd.2026.100295_bib4","first-page":"601","article-title":"Pharmacokinetic drug-drug interaction and their implication in clinical management","volume":"18","author":"Palleria","year":"2013","journal-title":"J Res Med Sci"},{"issue":"4","key":"10.1016\/j.dmd.2026.100295_bib5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","article-title":"Medicinal chemical properties of successful central nervous system drugs","volume":"2","author":"Pajouhesh","year":"2005","journal-title":"NeuroRx"},{"issue":"1-3","key":"10.1016\/j.dmd.2026.100295_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2013.06.035","article-title":"CYP450 pharmacogenetic treatment strategies for antipsychotics: a review of the evidence","volume":"149","author":"Ravyn","year":"2013","journal-title":"Schizophr Res"},{"issue":"11","key":"10.1016\/j.dmd.2026.100295_bib7","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/17425255.2022.2160317","article-title":"CYP2D6 pharmacogenetics and phenoconversion in personalized medicine","volume":"18","author":"Nahid","year":"2022","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100295_bib8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.tpj.6500285","article-title":"Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity","volume":"5","author":"Ingelman-Sundberg","year":"2005","journal-title":"Pharmacogenomics J"},{"issue":"8","key":"10.1016\/j.dmd.2026.100295_bib10","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1124\/dmd.115.069096","article-title":"Evaluation of a New molecular entity as a victim of metabolic drug-drug interactions-an industry perspective","volume":"44","author":"Bohnert","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100295_bib11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/biom14010099","article-title":"A review of CYP-mediated drug interactions: mechanisms and in vitro drug-drug interaction assessment","volume":"14","author":"Lee","year":"2024","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.dmd.2026.100295_bib12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2125.2010.03799.x","article-title":"Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models","volume":"71","author":"Guest","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100295_bib13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s13318-024-00931-2","article-title":"Determination of intrinsic clearance and fraction unbound in human liver microsomes and in vitro-in vivo extrapolation of human hepatic clearance for marketed central nervous system drugs","volume":"50","author":"Palacharla","year":"2025","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"7","key":"10.1016\/j.dmd.2026.100295_bib14","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/00498254.2017.1354267","article-title":"Quantitative in vitro phenotyping and prediction of drug interaction potential of CYP2B6 substrates as victims","volume":"48","author":"Palacharla","year":"2018","journal-title":"Xenobiotica"},{"issue":"2","key":"10.1016\/j.dmd.2026.100295_bib15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3109\/00498254.2014.945196","article-title":"Chemical inhibitors of CYP450 enzymes in liver microsomes: combining selectivity and unbound fractions to guide selection of appropriate concentration in phenotyping assays","volume":"45","author":"Nirogi","year":"2015","journal-title":"Xenobiotica"},{"issue":"2","key":"10.1016\/j.dmd.2026.100295_bib16","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/00498254.2018.1434913","article-title":"Methoxsalen as an in vitro phenotyping tool in comparison with 1-aminobenzotriazole","volume":"49","author":"Palacharla","year":"2019","journal-title":"Xenobiotica"},{"issue":"7","key":"10.1016\/j.dmd.2026.100295_bib17","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1124\/dmd.110.032649","article-title":"Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data","volume":"38","author":"Gertz","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100295_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105425","article-title":"Absorption, distribution, metabolism, excretion (ADME), drug-drug interaction potential and prediction of human pharmacokinetics of SUVN-G3031, a novel histamine 3 receptor (H3R) inverse agonist in clinical development for the treatment of narcolepsy","volume":"152","author":"Nirogi","year":"2020","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"10.1016\/j.dmd.2026.100295_bib19","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ddtec.2004.10.002","article-title":"'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions","volume":"1","author":"Rostami-Hodjegan","year":"2004","journal-title":"Drug Discov Today Technol"},{"issue":"12","key":"10.1016\/j.dmd.2026.100295_bib20","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1124\/dmd.112.047233","article-title":"Statistical methods for analysis of time-dependent inhibition of cytochrome p450 enzymes","volume":"40","author":"Yates","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.dmd.2026.100295_bib21","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1124\/dmd.108.026252","article-title":"Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction","volume":"37","author":"Fahmi","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2026.100295_bib22","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2174\/138920007782109733","article-title":"Prediction of intestinal first-pass drug metabolism","volume":"8","author":"Yang","year":"2007","journal-title":"Curr Drug Metab"},{"issue":"2","key":"10.1016\/j.dmd.2026.100295_bib23","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.clpt.2004.04.003","article-title":"Time response of cytochrome P450 1A2 activity on cessation of heavy smoking","volume":"76","author":"Faber","year":"2004","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.dmd.2026.100295_bib24","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2174\/138920008784746382","article-title":"Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions","volume":"9","author":"Yang","year":"2008","journal-title":"Curr Drug Metab"},{"issue":"6","key":"10.1016\/j.dmd.2026.100295_bib25","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1124\/dmd.105.004077","article-title":"In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude","volume":"33","author":"Venkatakrishnan","year":"2005","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.dmd.2026.100295_bib26","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1124\/dmd.107.018663","article-title":"A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro","volume":"36","author":"Fahmi","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100295_bib27","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.2147\/NDT.S67470","article-title":"Profile of agomelatine and its potential in the treatment of generalized anxiety disorder","volume":"11","author":"Levitan","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"6","key":"10.1016\/j.dmd.2026.100295_bib28","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1517\/17425255.2014.908185","article-title":"Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism","volume":"10","author":"Citrome","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100295_bib29","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.smrv.2007.12.005","article-title":"Efficacy and clinical safety of ramelteon: an evidence-based review","volume":"12","author":"Sateia","year":"2008","journal-title":"Sleep Med Rev"},{"issue":"6","key":"10.1016\/j.dmd.2026.100295_bib30","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0009-9236(97)90095-3","article-title":"Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans","volume":"61","author":"Becquemont","year":"1997","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.dmd.2026.100295_bib31","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.clpt.2005.02.010","article-title":"Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation","volume":"77","author":"Turpeinen","year":"2005","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dmd.2026.100295_bib32","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/clpt.2011.140","article-title":"Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine","volume":"90","author":"Peltoniemi","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.dmd.2026.100295_bib33","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1177\/009127002762491307","article-title":"Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics","volume":"42","author":"Belle","year":"2002","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100295_bib34","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/00004714-199708000-00008","article-title":"Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers","volume":"17","author":"Alderman","year":"1997","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100295_bib35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00228-006-0129-8","article-title":"Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl","volume":"63","author":"Harris","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.dmd.2026.100295_bib36","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1177\/0091270007304103","article-title":"Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies","volume":"47","author":"Nakashima","year":"2007","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100295_bib37","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1067\/mcp.2003.28","article-title":"Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers","volume":"73","author":"Skinner","year":"2003","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100295_bib38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0165-1781(95)02822-6","article-title":"Paroxetine shifts imipramine metabolism","volume":"59","author":"Albers","year":"1996","journal-title":"Psychiatry Res"},{"issue":"5","key":"10.1016\/j.dmd.2026.100295_bib41","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1365-2125.2007.03070.x","article-title":"Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction","volume":"65","author":"Youdim","year":"2008","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100295_bib42","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1515\/dmdi-2014-0005","article-title":"Lurasidone drug-drug interaction studies: a comprehensive review","volume":"29","author":"Chiu","year":"2014","journal-title":"Drug Metabol Drug Interact"},{"issue":"4","key":"10.1016\/j.dmd.2026.100295_bib43","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/0091270008331133","article-title":"Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm","volume":"49","author":"Stoch","year":"2009","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100295_bib44","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/clpt.1994.60","article-title":"Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole","volume":"55","author":"Olkkola","year":"1994","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dmd.2026.100295_bib45","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.clinthera.2009.02.022","article-title":"Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers","volume":"31","author":"Krishna","year":"2009","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.dmd.2026.100295_bib46","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.clpt.2005.11.016","article-title":"Comparison of midazolam and simvastatin as cytochrome P450 3A probes","volume":"79","author":"Chung","year":"2006","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.dmd.2026.100295_bib48","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2125.2005.02507.x","article-title":"Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics","volume":"61","author":"Grimm","year":"2006","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100295_bib49","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-2710.2011.01271.x","article-title":"Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers","volume":"37","author":"Mahatthanatrakul","year":"2012","journal-title":"J Clin Pharm Ther"},{"issue":"11","key":"10.1016\/j.dmd.2026.100295_bib50","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.clinthera.2014.08.003","article-title":"Influence of CYP3A4 induction\/inhibition on the pharmacokinetics of vilazodone in healthy subjects","volume":"36","author":"Boinpally","year":"2014","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.dmd.2026.100295_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100223","article-title":"Fraction metabolized by cytochrome P450 enzymes: a comprehensive evaluation of the translatability of an in vitro HepatoPac assay","volume":"54","author":"Klammers","year":"2026","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100295_bib52","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.2147\/PPA.S235104","article-title":"Transdermal asenapine in schizophrenia: a systematic review","volume":"14","author":"Carrithers","year":"2020","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"10.1016\/j.dmd.2026.100295_bib53","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/jcph.1946","article-title":"Brexpiprazole pharmacokinetics in CYP2D6 poor metabolizers: using physiologically based pharmacokinetic modeling to optimize time to effective concentrations","volume":"62","author":"Elmokadem","year":"2022","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.dmd.2026.100295_bib54","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1124\/dmd.116.072363","article-title":"Stereoselective metabolism of bupropion to OH-bupropion, threohydrobupropion, erythrohydrobupropion, and 4'-OH-bupropion in vitro","volume":"44","author":"Sager","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmd.2026.100295_bib55","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1124\/dmd.121.000765","article-title":"Estimation of fraction metabolized by cytochrome P450 enzymes using long-term cocultured human hepatocytes","volume":"50","author":"Klammers","year":"2022","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100295_bib56","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0024-3205(00)00613-5","article-title":"Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes","volume":"67","author":"Yoshii","year":"2000","journal-title":"Life Sci"},{"issue":"3","key":"10.1016\/j.dmd.2026.100295_bib57","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/S0022-3565(25)13120-0","article-title":"The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways","volume":"277","author":"Nielsen","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.dmd.2026.100295_bib58","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1515\/dmpt-2016-0028","article-title":"Improvement of the chemical inhibition phenotyping assay by cross-reactivity correction","volume":"31","author":"Njuguna","year":"2016","journal-title":"Drug Metab Pers Ther"},{"issue":"6","key":"10.1016\/j.dmd.2026.100295_bib59","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1124\/dmd.108.020446","article-title":"Integrated in vitro analysis for the in vivo prediction of cytochrome P450-mediated drug-drug interactions","volume":"36","author":"McGinnity","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100295_bib60","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/00498254.2017.1422156","article-title":"Direct and quantitative evaluation of the major human CYP contribution (fmCYP) to drug clearance using the in vitro Silensomes\u2122 model","volume":"49","author":"Parmentier","year":"2019","journal-title":"Xenobiotica"},{"issue":"8","key":"10.1016\/j.dmd.2026.100295_bib61","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s002280050679","article-title":"In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol","volume":"55","author":"Pan","year":"1999","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100295_bib62","doi-asserted-by":"crossref","first-page":"742","DOI":"10.3390\/ph16050742","article-title":"Ketamine and the disinhibition hypothesis: neurotrophic factor-mediated treatment of depression","volume":"16","author":"Borsellino","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"10.1016\/j.dmd.2026.100295_bib63","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/1060028020936597","article-title":"Lumateperone: a novel antipsychotic for schizophrenia","volume":"55","author":"Greenwood","year":"2021","journal-title":"Ann Pharmacother"},{"issue":"5","key":"10.1016\/j.dmd.2026.100295_bib64","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40262-016-0465-5","article-title":"Pharmacokinetics and pharmacodynamics of lurasidone hydrochloride, a second-generation antipsychotic: a systematic review of the published literature","volume":"56","author":"Greenberg","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.dmd.2026.100295_bib65","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1124\/dmd.109.030551","article-title":"Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator","volume":"38","author":"Jornil","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"20","key":"10.1016\/j.dmd.2026.100295_bib66","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1007\/s00216-024-05409-3","article-title":"Binding studies of promethazine and its metabolites with human serum albumin by high-performance affinity chromatography and molecular docking in the presence of codeine","volume":"416","author":"Coelho","year":"2024","journal-title":"Anal Bioanal Chem"},{"issue":"3-4","key":"10.1016\/j.dmd.2026.100295_bib67","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1515\/DMDI.2006.21.3-4.187","article-title":"In vitro studies on quetiapine metabolism using the substrate depletion approach with focus on drug-drug interactions","volume":"21","author":"Hasselstr\u00f8m","year":"2006","journal-title":"Drug Metabol Drug Interact"},{"issue":"8","key":"10.1016\/j.dmd.2026.100295_bib68","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1124\/dmd.110.034009","article-title":"Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics","volume":"38","author":"Obach","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.dmd.2026.100295_bib69","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70358","article-title":"A modeling investigation of the CYP1A drug interactions of riluzole","volume":"18","author":"Malik","year":"2025","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.dmd.2026.100295_bib70","first-page":"131","article-title":"CYP2D6 polymorphisms and their influence on risperidone treatment","volume":"9","author":"Puangpetch","year":"2016","journal-title":"Pharmgenomics Pers Med"},{"issue":"4","key":"10.1016\/j.dmd.2026.100295_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100062","article-title":"Evaluation of small interfering RNA-dependent knockdowns of drug-metabolizing enzymes in multiwell array culture of primary human hepatocyte spheroids for estimation of fraction metabolized","volume":"53","author":"Br\u00fccker","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.dmd.2026.100295_bib72","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3390\/pharmaceutics12100942","article-title":"Physiologically based pharmacokinetic modeling of transdermal selegiline and its metabolites for the evaluation of disposition differences between healthy and special populations","volume":"12","author":"Puttrevu","year":"2020","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.dmd.2026.100295_bib73","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1124\/dmd.104.002428","article-title":"Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study","volume":"33","author":"Obach","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100295_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1636919","article-title":"Characterization of trazodone metabolic pathways and species-specific profiles","volume":"16","author":"Petrucci","year":"2025","journal-title":"Front Pharmacol"},{"issue":"11","key":"10.1016\/j.dmd.2026.100295_bib75","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1124\/dmd.107.015883","article-title":"A comparison of 2-phenyl-2-(1-piperidinyl)propane (ppp), 1,1',1''-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6","volume":"35","author":"Walsky","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.dmd.2026.100295_bib76","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1124\/dmd.120.000111","article-title":"Evaluation of in vitro models for assessment of human intestinal metabolism in drug discovery","volume":"48","author":"Davies","year":"2020","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmd.2026.100295_bib77","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.124.001660","article-title":"Projections of drug-drug interactions caused by time-dependent inhibitors of cytochrome P450 1A2, 2B6, 2C8, 2C9, 2C19, and 2D6 using in vitro data in static and dynamic models","volume":"52","author":"Tseng","year":"2024","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100295_bib78","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1124\/dmd.121.000718","article-title":"Predictive in vitro-in vivo extrapolation for time dependent inhibition of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 using pooled human hepatocytes, human liver microsomes, and a simple mechanistic static model","volume":"50","author":"Ramsden","year":"2022","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2026.100295_bib79","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1124\/dmd.31.3.289","article-title":"Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine","volume":"31","author":"Bertelsen","year":"2003","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.dmd.2026.100295_bib80","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1124\/dmd.116.071761","article-title":"The impact of the hepatocyte-to-plasma pH gradient on the prediction of hepatic clearance and drug-drug interactions for CYP2D6 substrates","volume":"44","author":"Roug\u00e9e","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmd.2026.100295_bib81","first-page":"415","article-title":"Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2","volume":"70","author":"Yao","year":"2001","journal-title":"Clin Pharmacol Ther"},{"issue":"10-11","key":"10.1016\/j.dmd.2026.100295_bib82","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.3109\/00498250701620700","article-title":"Comparison of different approaches to predict metabolic drug-drug interactions","volume":"37","author":"Einolf","year":"2007","journal-title":"Xenobiotica"},{"issue":"6","key":"10.1016\/j.dmd.2026.100295_bib83","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1208\/s12248-023-00863-w","article-title":"Quantitative translation of substrate intrinsic clearance from recombinant CYP1A1 to humans","volume":"25","author":"Di","year":"2023","journal-title":"AAPS J"},{"issue":"8","key":"10.1016\/j.dmd.2026.100295_bib84","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2165\/11592620-000000000-00000","article-title":"Quantitative prediction of cytochrome P450 (CYP) 2D6-mediated drug interactions","volume":"50","author":"Tod","year":"2011","journal-title":"Clin Pharmacokinet"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T10:15:20Z","timestamp":1779790520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626000644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":80,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0090955626000644"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100295","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In Vitro Reaction Phenotyping and Projection of Drug Interactions Mediated by Cytochrome P450 Enzymes for Central Nervous System Drugs as Victims: Implications for Safety in Vulnerable Populations","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100295","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100295"}}